Short answer
Regeneron Pharmaceuticals (REGN) filed its Q3 2025 10-Q quarterly report on Oct 28, 2025 for the quarter ended Sep 30, 2025. Quarterly revenue was $3.8B (up 0.9% year over year) with net income of $1.5B.
Q3 2025 key financials · XBRL
- Revenue
- $3.8B
- +0.9% YoY · +2.1% QoQ
- Net income
- $1.5B
- +8.9% YoY · +4.9% QoQ
- Operating margin
- 27.3%
- EPS (diluted)
- $13.59
- +17.7% YoY · +6.6% QoQ
Source: XBRL data from the Regeneron Pharmaceuticals (REGN) Q3 2025 10-Q on SEC EDGAR. USD.
Regeneron Pharmaceuticals Q3 2025 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Revenue $3.75B in Q3 FY2025, up slightly by $33.6M from $3.72B in Q3 FY2024
- Net income $1.46B in Q3 FY2025 vs $1.34B Q3 FY2024; operating margin 27.3% vs 31.7% YoY (operating income $1.03B vs $1.18B)
- Best segment: Dupixent collaboration revenue up $353.6M YoY to $1.62B in Q3; worst: EYLEA total US sales down $426M to $1.11B due to competition and pricing pressures
- Cash/cash equivalents flat at $2.5B; Operating cash flow increased $650.5M to $3.81B in first nine months; $2.16B remain for share repurchases
- Near-term headwinds: FDA delays and Complete Response Letters for EYLEA HD due to manufacturing inspection; ongoing competition and pricing pressure on EYLEA product line
Risk Factors
- New risk: FDA Complete Response Letters (CRLs) for odronextamab BLA and EYLEA HD pre-filled syringe delayed approvals in 2025 due to manufacturing inspection issues
- Most updated risk: Biosimilar competition intensifying post-EYLEA US exclusivity expiration May 2024, causing 39-41% decline in US EYLEA sales in 2025
- Regulatory/legal risk: Ongoing US DOJ civil investigations regarding business activities may lead to penalties or enforcement actions (see Note 12)
- Operational/market risk: Dependence on two distributors for 77% of US gross product revenue poses concentration risk affecting near-term sales distribution
- Financial risk: Heavy reliance on collaborators Bayer and Sanofi for commercialization outside US; termination or breach could materially impair global sales and revenue
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Regeneron Pharmaceuticals quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.